Iambic Therapeutics Selects Lambda Cloud to Help Meet Compute Demands of its Generative AI Drug Discovery Models
Lambda , the GPU cloud company founded by AI engineers and powered by NVIDIA GPUs, today announced that Iambic Therapeutics , a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, has selected Lambda Cloud to provide NVIDIA H100 Tensor Core GPUs to accelerate training and inference for its leading generative AI drug discovery models.
- Lambda , the GPU cloud company founded by AI engineers and powered by NVIDIA GPUs, today announced that Iambic Therapeutics , a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, has selected Lambda Cloud to provide NVIDIA H100 Tensor Core GPUs to accelerate training and inference for its leading generative AI drug discovery models.
- Iambic’s generative AI drug discovery models include NeuralPLexer , a state-of-the-art model for predicting protein-ligand structures, including conformation changes resulting from drug interactions.
- Enabling transformer models in drug discovery efforts is an important step toward unlocking AI’s potential for advancing therapeutics,” said Stephen Balaban, Lambda CEO and co-founder.
- Click here to learn more about Lambda’s cloud offerings for AI training and inference.